- Second-generation norovirus constructs produce statistically significant increases in GI.1 and GII.4 norovirus blocking antibodies (141% and 94%, respectively) compared…
- Enables streamlined stability testing and release of higher quality AAV-based gene therapy products. - Provides much needed European capacity…
SAN DIEGO, June 09, 2025 (GLOBE NEWSWIRE) -- Maravai LifeSciences Holdings, Inc. (NASDAQ: MRVI), a global provider of life science…
Will provide expertise across ModeX’s portfolio of next generation multispecific antibodies for complex diseases involving the immune system, including cancer…
Atopic dermatitis is a chronic disease that disproportionately impacts communities of color Dupixent achieved 75% or greater improvement in overall…
JACKSONVILLE, Fla., June 5, 2025 /PRNewswire/ -- Advanced Biological Research Group (ABRG), a 501c3, has announced its second study to…
The first-of-its-kind report includes results from multiple surveys revealing just how badly dogs around the country are itching for relief.Data…
CAMBRIDGE, United Kingdom and SAN DIEGO, June 05, 2025 (GLOBE NEWSWIRE) -- DIOSynVax, a clinical-stage biotechnology company at the forefront…
Oncovita receives FDA Orphan Drug Designation for its lead oncolytic virus candidate MVdeltaC in the treatment of pleural mesothelioma Paris,…
Collaboration leverages cutting-edge reformulation expertise to generate cross-species insights, fast-track human clinical programs, and seeks to capture commercial potential in…